Previously, anti-CD19 antibody drug conjugates such as coltuximab ravtansine (SAR3419) demonstrated promising antitumour activity with acceptable safety profile in NHL [11]; however, the phase 2 study was discontinued prematurely due to the low clinical response rates observed in patients [12]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.